<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03162783</url>
  </required_header>
  <id_info>
    <org_study_id>ADX-102-DES-007</org_study_id>
    <nct_id>NCT03162783</nct_id>
  </id_info>
  <brief_title>A Randomized, Double Masked, Clinical Study of Subjects With Dry Eye Syndrome</brief_title>
  <official_title>A Single-Center, Phase 2a, Randomized, Double Masked, Clinical Study to Assess the Safety, Tolerability, and Pharmacodynamic Activity of ADX-102 Ophthalmic Solution in Subjects With Dry Eye Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aldeyra Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aldeyra Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate the safety, tolerability, and pharmacodynamic
      activity of ADX-102 Ophthalmic Solutions and ADX-102 Ophthalmic Lipid Solution in subjects
      with dry eye syndrome.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 15, 2017</start_date>
  <completion_date type="Actual">July 6, 2017</completion_date>
  <primary_completion_date type="Actual">July 6, 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assess safety and tolerability of ADX-102 formulations using adverse event query.</measure>
    <time_frame>Safety Assessment Period (Day 1 through Day 29)</time_frame>
    <description>Evaluate the safety and tolerability of ADX-102 formulations in subjects with dry eye syndrome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ADX-102 on ocular discomfort using the Ora Calibra® Ocular Discomfort scale.</measure>
    <time_frame>Efficacy assessment period (Day 1 through Day 29)</time_frame>
    <description>Evaluate the symptoms of ADX-102 on ocular discomfort in subjects with dry eye syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ADX-102 on dry eye syndrome symptoms using the Symptom Assessment in Dry Eye (SANDE) scale.</measure>
    <time_frame>Efficacy assessment period (Day 1 through Day 29)</time_frame>
    <description>Evaluate the dry eye symptoms of ADX-102 in subjects with dry eye syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ADX-102 on dry eye syndrome using the Ocular Surface and Disease Index (OSDI) © questionnaire.</measure>
    <time_frame>Efficacy assessment period (Day 1 through Day 29)</time_frame>
    <description>Evaluate the symptoms of ADX-102 in subjects with dry eye syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ADX-102 on tear film break-up time (TFBUT©).</measure>
    <time_frame>Efficacy assessment period (Day 1 through Day 29)</time_frame>
    <description>Evaluate tear film break-up time of ADX-102 in subjects with dry eye syndrome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Efficacy of ADX-102 on fluorescein staining using the Ora Calibra® scale.</measure>
    <time_frame>Efficacy assessment period (Day 1 through Day 29)</time_frame>
    <description>Evaluate fluorescein staining of ADX-102 in subjects with dry eye syndrome.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">51</enrollment>
  <condition>Dry Eye Syndromes</condition>
  <arm_group>
    <arm_group_label>ADX-102 Ophthalmic Solution (0.5%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADX-102 Ophthalmic Solution (0.1%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>ADX-102 Ophthalmic Lipid Solution (0.5%)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-102 Ophthalmic Solution (0.5%)</intervention_name>
    <description>ADX-102 Ophthalmic Solution (0.5%) administered for approximately 4 weeks.</description>
    <arm_group_label>ADX-102 Ophthalmic Solution (0.5%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-102 Ophthalmic Solution (0.1%)</intervention_name>
    <description>ADX-102 Ophthalmic Solution (0.1%) administered for approximately 4 weeks.</description>
    <arm_group_label>ADX-102 Ophthalmic Solution (0.1%)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ADX-102 Ophthalmic Lipid Solution (0.5%)</intervention_name>
    <description>ADX-102 Ophthalmic Lipid Solution administered for approximately 4 weeks.</description>
    <arm_group_label>ADX-102 Ophthalmic Lipid Solution (0.5%)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Be at least 18 years of age of either gender and any race;

          -  Have a reported history of dry eye for at least 6 months prior to Visit 1;

          -  Have a history of use or desire to use eye drops for dry eye symptoms within 6 months
             of Visit 1;

        Exclusion Criteria:

          -  Have any clinically significant slit lamp findings at Visit 1 that may include active
             blepharitis, meibomian gland dysfunction (MGD), lid margin inflammation, or active
             ocular allergies that require therapeutic treatment, and/or in the opinion of the
             investigator may interfere with study parameters;

          -  Be diagnosed with an ongoing ocular infection (bacterial, viral, or fungal), or active
             ocular inflammation at Visit 1;

          -  Have worn contact lenses within 7 days of Visit 1 or anticipate using contact lenses
             during the study;

          -  Have previously had laser-assisted in situ keratomileusis (LASIK) surgery within the
             last 12 months;

          -  Have used cyclosporine 0.05% or lifitigrast 5.0% ophthalmic solution within 45 days of
             Visit 1;

          -  Have any planned ocular and/or lid surgeries over the study period or any ocular
             surgery within the last 6 months;

          -  Be using or anticipate using temporary punctal plugs during the study that have not
             been stable within 30 days of Visit 1;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Andover Eye Associates</name>
      <address>
        <city>Andover</city>
        <state>Massachusetts</state>
        <zip>01810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 19, 2017</study_first_submitted>
  <study_first_submitted_qc>May 19, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">May 22, 2017</study_first_posted>
  <last_update_submitted>October 17, 2017</last_update_submitted>
  <last_update_submitted_qc>October 17, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Aldeyra</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Keratoconjunctivitis Sicca</mesh_term>
    <mesh_term>Dry Eye Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

